Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.

被引：0

作者：

Moore, Kathleen N.

Bendell, Johanna C.

Olszanski, Anthony J.

Desai, Madhuri

Jansen, Mendel

Scheyer, Richard David

Senaldi, Giorgio

LoRusso, Patricia

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Tennessee Oncol, Nashville, TN USA

[4] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[5] Daiichi Sankyo Co Ltd, Edison, NJ USA

[6] Daiichi Sankyo Co Ltd, Gerrards Cross, England

[7] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2519

引用

页数：1